Treatment of lysosomal storage disorders

British Medical Journal

Volumn 327, Issue 7413, 2003, Pages 462-463

  Mehta, Atul B ^a   Lewis, Susan ^b   Laverey, Christine ^c  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b Gauchers Association   (United Kingdom)

^c Society for Mucopolysaccharide Diseases   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; GLUCOSYLCERAMIDASE; IMIGLUCERASE; MIGLUSTAT;

AWARENESS; EDITORIAL; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; HUMAN; LYSOSOME STORAGE DISEASE; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL;

EID: 0041352256     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.327.7413.462     Document Type: Editorial

References (9)

1. Beutler E, Grabowski GA. Gaucher's disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular basis of inherited disease. 8th ed. USA: McGraw Hill, 2001:3635-68.
2. Mehta A. New developments in the management of Anderson-Fabry disease. QJ Med 2002;95:647-53.
3. Meikle PJ, Hopwood JJ. Lysosomal storage disorders: Prevalence and newborn screening. Gaucher Clin Perspect 2000;8:1-5.
4. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001;285:2743-9.
5. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human α-galactosidase A replacement in Fabry's disease. N Engl J Med 2001;345:9-16.
6. Pastores GM, Thadhani R. Enzyme replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-3.
7. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:1407-11.
8. Morgan SH, Crawford d'A. Anderson-Fabry disease: a commonly missed diagnosis. BMJ 1988;297:872-3.
9. Cox T, Lachmann R, Hollak C, Aerts J, van Weely S, Hrebicek M, et al. A novel treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000;355:1481-5.